{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:00:52Z","timestamp":1761663652513,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":635,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.5604\/01.3001.0010.2732","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T10:10:48Z","timestamp":1502273448000},"page":"734-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination"],"prefix":"10.1016","volume":"16","author":[{"given":"Akihiro","family":"Tamori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang","family":"Hai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawako","family":"Uchida-Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritsuzo","family":"Kozuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Motoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsushi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuga","family":"Teranishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.5604\/01.3001.0010.2732_bib0010","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1473-3099(12)70060-9","article-title":"Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care","volume":"12","author":"Pearlman","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.5604\/01.3001.0010.2732_bib0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2893.2009.01163.x","article-title":"Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders","volume":"17","author":"Imai","year":"2010","journal-title":"J Viral Hepat"},{"key":"10.5604\/01.3001.0010.2732_bib0020","first-page":"518","article-title":"Effect of aging on risk for hepatocel-lular carcinoma in chronic hepatitis C virus infection","volume":"52","author":"Asahina","year":"2010","journal-title":"Hepa-tology"},{"key":"10.5604\/01.3001.0010.2732_bib0025","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.5604\/01.3001.0010.2732_bib0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","article-title":"Simeprevir with peginterferon\/ ribavirin for treatment-na\u00efve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial","volume":"61","author":"Hayashi","year":"2014","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0010.2732_bib0035","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/hepr.12689","article-title":"Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with HCV genotype 1b","volume":"46","author":"Tamori","year":"2016","journal-title":"Hepatol Res"},{"key":"10.5604\/01.3001.0010.2732_bib0040","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00535-015-1120-x","article-title":"Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study","volume":"51","author":"Hayashi","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.5604\/01.3001.0010.2732_bib0045","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0010.2732_bib0050","unstructured":"JSH Guidelines for the Management of Hepatitis C Virus Infection: 5.1th edition 2016. In Japanese http:\/\/www.jsh.or.jp\/ files\/uploads\/HCV_GL_ver5.1_Oct08_final.pdf"},{"key":"10.5604\/01.3001.0010.2732_bib0055","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/liv.13049","article-title":"Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis","volume":"36","author":"Kao","year":"2016","journal-title":"Liver Int"},{"key":"10.5604\/01.3001.0010.2732_bib0060","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcv.2015.02.005","article-title":"Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort","volume":"65","author":"Shepherd","year":"2015","journal-title":"J Clin Virol"},{"key":"10.5604\/01.3001.0010.2732_bib0065","unstructured":"AASLD and IDSA Recommendations for Testing, Managing, and Treating Hepatitis C, 2014 Available at http:\/\/ www.hcvguidelines.org"},{"key":"10.5604\/01.3001.0010.2732_bib0070","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.5604\/01.3001.0010.2732_bib0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/jgh.12376","article-title":"Relationship between inosine tri-phosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin","volume":"29","author":"Hai","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.5604\/01.3001.0010.2732_bib0080","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00535-016-1225-x","article-title":"Efficacy of daclatasvir\/asunapre-vir according to resistance-associated variants in chronic hepatitis C with genotype 1","volume":"52","author":"Iio","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.5604\/01.3001.0010.2732_bib0085","series-title":"Hepatol Res","article-title":"Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis","author":"Ogawa","year":"2016"},{"key":"10.5604\/01.3001.0010.2732_bib0090","series-title":"J Gastroenterol Hepatol","article-title":"Real-World Efficacy and Safety of Daclatasvir and Asunaprevir Therapy for Hepatitis C Virus-Infected Cirrhosis Patients","author":"Morio","year":"2016"},{"key":"10.5604\/01.3001.0010.2732_bib0095","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/hepr.12621","article-title":"Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients","volume":"46","author":"Miyaki","year":"2016","journal-title":"Hepatol Res"},{"key":"10.5604\/01.3001.0010.2732_bib0100","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-in-duced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0010.2732_bib0105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0010.2732_bib0110","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interfer-on-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0010.2732_bib0115","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.cgh.2013.11.033","article-title":"Post-treatment levels of \u03b1-feto-protein predict incidence of hepatocellular carcinoma after interferon therapy","volume":"12","author":"Oze","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.5604\/01.3001.0010.2732_bib0120","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2016.07.043","article-title":"The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma","volume":"65","author":"Minami","year":"2016","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0010.2732_bib0125","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbu-vir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.5604\/01.3001.0010.2732_bib0130","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep.27972","article-title":"Randomized phase 3 trial of om-bitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis","volume":"62","author":"Kumada","year":"2015","journal-title":"Hepatology"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119304326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119304326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:34:56Z","timestamp":1761647696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119304326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1665268119304326"],"URL":"https:\/\/doi.org\/10.5604\/01.3001.0010.2732","relation":{},"ISSN":["1665-2681"],"issn-type":[{"type":"print","value":"1665-2681"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/01.3001.0010.2732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}